Skip to main content

FDA Approves Pediatric Everolimus for Treatment of SEGA


August 29, 2012 — The US Food and Drug Administration (FDA) announced approval today of a new pediatric dosage form of everolimus for use in very young children with a rare brain tumor.
The new formulation, everolimus tablets for oral suspension (Afinitor Disperz, Novartis), is the first approved pediatric-specific dosage form developed for pediatric tumors, the FDA notes. This new dosage formulation is able to dissolve more rapidly and provides for smaller dose increments, thus allowing for greater dosing flexibility.
The product is indicated for use in the treatment of subependymal giant cell astrocytoma (SEGA).
Everolimus was granted an accelerated approval in 2010 to treat SEGA in patients with tuberous sclerosis complex.
The new formulation is recommended for patients aged 1 year or older with tuberous sclerosis complex who are diagnosed with inoperable SEGA. Before the approval of this new formulation, everolimus was not recommended for use in children younger than 3 years.
The drug label was also updated to include longer-term safety follow-up data.
"Appropriate pediatric dosage forms, such as Afinitor Disperz, help to ensure the safe and effective use of oncology drugs in children," said Richard Pazdur, MD, director of the Office of Oncology Drug Products at the FDA's Center for Drug Evaluation and Research, in a statement. "In addition, today's approval demonstrates the value of further studying a drug to better characterize its benefits and how it should be used in pediatric patients."
Defects in mTOR Pathway
Tuberous sclerosis complex is a rare genetic disorder caused by defects in the TSC1 and TSC2 genes that negatively control the mammalian target of rapamycin (mTOR). It typically causes the growth of benign tumors in many vital organs including the brain, kidneys, heart, eyes, lungs, and skin. SEGAs are considered a major diagnostic feature of the disorder, and can occur in up to 20% of children and adults.
As previously reported by Medscape Medical News, research has shown that inhibitors of the mTOR pathway have a profound effect on the tuberous sclerosis complex, both on the nonmalignant tumors in the brain and skin lesions.
Surgery has thus far been the only option for patients with SEGA, but it is highly invasive, as SEGAs tend to be situated deep in the middle of the brain, near the ventricles. In addition, patients can also have several SEGAs growing bilaterally, which can make surgical resection difficult.
Both everolimus and its pediatric formulation remain under accelerated approval for treatment of SEGA in patients with tuberous sclerosis complex.
When the drug received its accelerated approval for this indication in 2010, the decision was based on data from a single arm study that included 28 pediatric patients and adults.
The manufacturer has now supplied data from the larger and more recent Phase III EXIST-1 trial that included 117 pediatric and adult patients randomly assigned to take everolimus or a placebo daily. The results showed that 35% (27 of 78) receiving everolimus experienced a reduction of 50% or more in the total volume of all their SEGAs, relative to baseline, whereas the placebo group showed no reduction (P < .0001).
Everolimus is manufactured by Novartis, and is a derivative of sirolimus that inhibits mTOR. It has already received FDA approval for a number of other indications including advanced renal cell carcinoma that has progressed after treatment with other cancer therapies (2009); as a treatment for adults with progressive advanced neuroendocrine tumors of pancreatic origin (2011); for adults with tuberous sclerosis complex who have renal angiomyolipomas not requiring immediate surgery (2012); and for use in combination with exemestane (Aromasin, Pfizer) to treat certain postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (2012).

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Approvals: Pazopanib for Advanced Soft Tissue Sarcoma

CLINICAL CONTEXT Pazopanib was first approved by the US Food and Drug Administration (FDA) in 2009 when it became the sixth drug approved to treat advanced renal cell carcinoma. It is a small molecule with a mechanism of action as a tyrosine kinase inhibitor, specifically targeting receptors involved in angiogenesis and tumor cell proliferation. These include vascular endothelial growth-factor receptors 1, 2, and 3; platelet-derived growth-factor receptors α and β; fibroblast growth-factor receptors 1 and 3; stem cell factor receptors; interleukin-2-inducible T-cell kinase; leukocyte-specific protein tyrosine kinase; and transmembrane glycoprotein-receptor tyrosine kinase. STUDY SYNOPSIS AND PERSPECTIVE The FDA has approved pazopanib ( Votrient ) for the treatment of advanced soft tissue sarcoma in patients who have received previous chemotherapy. Pazopanib is already marketed for the treatment of advanced renal cell carcinoma; when it was approved in 2009, it became the six...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more